Bayer AG head of pharmaceuticals research and development Christian Rommel acknowledges that the conglomerate is working its way through a difficult period, but he oversees an R&D pipeline that needs more time to show that the company’s investments in technologies like chemoproteomics and cell and gene therapies will pay off. It’s a big ask for investors who have been waiting a while already for Bayer’s strategy to deliver significant returns.
Key Takeaways
-
Bayer is facing a no-growth period for its pharma business at a time when the conglomerate has challenges across all three of its business groups.
...
“We are in a resilience phase,” Rommel told Scrip in an interview during the J.P. Morgan Healthcare Conference. “We have to renew the top line, we have to rebuild the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
